Association of ustekinumab and briakinumab with major adverse cardiovascular events: An appraisal of meta-analyses and industry sponsored pooled analyses to date

Safety concerns have been raised regarding possible association of major adverse cardiovascular events (MACEs) with use of anti-IL-12/23 biologic agents for the treatment of chronic plaque psoriasis (CPP). Ten MACEs have been recorded in actively-treated patients during the placebo-controlled phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Tzellos, Thrasivoulos, Kyrgidis, Athanassios, Trigoni, Anastasia, Zouboulis, Christos C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583893/
https://www.ncbi.nlm.nih.gov/pubmed/23467502
http://dx.doi.org/10.4161/derm.23100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583893/
https://www.ncbi.nlm.nih.gov/pubmed/23467502
http://dx.doi.org/10.4161/derm.23100

Ejemplares similares